Roche Expects Deliveries of Covid-19 Antibody in First Quarter

The transcript discusses WHO's recommendation against remdesivir, highlighting the increased demand for Regeneron's antibody cocktails despite manufacturing challenges. It covers the promising development of vaccines by Moderna and Pfizer, emphasizing the continued need for treatments. The process of Regeneron's FDA emergency authorization and production plans is detailed, along with the expected limited supply. The impact of the Biden administration on the pharmaceutical industry is also considered, with a focus on innovation and policy.

What is the expected timeline for FDA approval of Regeneron?

What does the speaker indicate about the supply of Regeneron doses?

How does the speaker view the impact of a Biden administration on drug companies?